CP-115 Optimisation of anti-interleukin biological therapies in psoriasis patient above 100 kg

BackgroundBiological agents targeting interleukin such as ustekinumab and secukinumab are strategies employed in psoriasis treatment. Ustekinumab requires double doses in patients over 100 kg, which implies an increase in costs due to the absence of a 90 mg injectable solution in our national market...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2017-03, Vol.24 (Suppl 1), p.A51-A51
Main Authors: Goldaracena, J Preciado, Goñi, N Larrea, Punset, M Coma, García, J Polo, Bayona, JI Yanguas, Bulnes, C Fontela, Elcano, R San Miguel, González, J Fernández, Zurbano, R Juanbeltz, Basarte, J Alfaro
Format: Article
Language:English
Subjects:
Cost control
Cytokines
Economic impact
Patients
Psoriasis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundBiological agents targeting interleukin such as ustekinumab and secukinumab are strategies employed in psoriasis treatment. Ustekinumab requires double doses in patients over 100 kg, which implies an increase in costs due to the absence of a 90 mg injectable solution in our national market. Secukinumab, recently approved for psoriasis, does not require dose modification based on weight.PurposeTo describe the experience and assess the clinical response and economic impact of switching from ustekinumab to secukinumab in moderate–severe plaque psoriasis patients weighing more than 100 kg in the maintenance phase with optimal (Psoriasis Area and Severity Index (PASI)
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2017-000640.114